Table 2 Medications used comparisons by gender
Variables | Male (n = 402) | Female (n = 270) |
|---|---|---|
During hospitalization | ||
Aspirin, n (%) | 402 (100) | 270 (100) |
Clopidogrel, n (%) | 368 (91.5) | 246 (91.1) |
Ticagrelor, n (%) | 32 (8.0) | 20 (7.4) |
Statins, n (%) | 380 (94.5) | 252 (93.3) |
ACEI/ARB, n (%) | 342 (85.1) | 220 (81.5)* |
Beta-blocker, n (%) | 330 (82.1) | 218 (80.7) |
LMWH, n (%) | 25 (6.2) | 12 (4.4) |
Warfarin, n (%) | 0 (0) | 0 (0) |
PPI, n (%) | 219 (54.5) | 152 (56.3) |
During follow-up | ||
Aspirin, n (%) | 398 (99.0) | 265 (98.1) |
Clopidogrel, n (%) | 362 (90.0) | 242 (89.6) |
Ticagrelor, n (%) | 28 (7.0) | 16 (5.9) |
Statins, n (%) | 380 (94.5) | 252 (93.3) |
ACEI/ARB, n (%) | 340 (84.6) | 215 (79.6)* |
Beta-blocker, n (%) | 330 (82.1) | 216 (80.0) |
LMWH, n (%) | 0 (0) | 0 (0) |
Warfarin, n (%) | 3 (0.7) | 2 (0.7) |
PPI, n (%) | 187 (46.5) | 132 (48.9) |